Cited 0 times in
Effect of beta2-adrenergic receptor polymorphism in asthma control of patients receiving combination treatment.
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, SH | - |
dc.contributor.author | Ye, YM | - |
dc.contributor.author | Hur, GY | - |
dc.contributor.author | Lee, HY | - |
dc.contributor.author | Jee, YK | - |
dc.contributor.author | Lee, SH | - |
dc.contributor.author | Holloway, JW | - |
dc.contributor.author | Park, HS | - |
dc.date.accessioned | 2010-12-20T06:39:50Z | - |
dc.date.available | 2010-12-20T06:39:50Z | - |
dc.date.issued | 2009 | - |
dc.identifier.issn | 0513-5796 | - |
dc.identifier.uri | http://repository.ajou.ac.kr/handle/201003/710 | - |
dc.description.abstract | PURPOSE: Combination treatment of inhaled corticosteroid (ICS) plus long-acting beta2-agonist (LABA) is widely used as a maintenance regimen for the management of asthma. This study evaluated the effect of the beta2-adrenergic receptor (ADRB2) polymorphism on lung function and asthma control with regular use of combination treatment of an inhaled ICS plus LABA.
MATERIALS AND METHODS: 43 Korean asthmatics who were symptomatic despite regular ICS use for at least 3 months were enrolled. For a 2-week run-in period, they received ICS (budesonide 800 microg/day) plus terbutaline (5 microg prn). as needed. During the 24-week active treatment period, they received budesonide 160 microg and formoterol 4.5 microg b.i.d. as maintenance and rescue medication. Pulmonary function and quality of life scores were monitored every 8 weeks; morning/evening peak expiratory flow meter (PEFR) was recorded daily. Patients were genotyped for ADRB2 Arg16Gly using single base extension methodology. RESULTS: During the run-in period, there were no significant between-group differences in lung function; after 8 weeks of active treatment, Arg/Arg patients had significantly higher forced expiratory volume in 1 secord (FEV(1)) and maximal mid-expiratory flow (MMEF) (p = 0.023 and p = 0.021, respectively), and better asthma control and quality of life after 24 weeks (p = 0.016 and p = 0.028, respectively). During treatment, there was a greater improvement in morning/evening PEFR in Arg/Arg patients. CONCLUSION: Asthmatic patients with the Arg/Arg genotype at codon 16 of ADRB2 achieve better asthma control with long-term regular use of combined budesonide and formoterol treatment, suggesting that the ADRB2 genotype may dictate choice of treatment strategy. | - |
dc.language.iso | en | - |
dc.subject.MESH | Administration, Inhalation | - |
dc.subject.MESH | Adrenal Cortex Hormones | - |
dc.subject.MESH | Adrenergic beta-Agonists | - |
dc.subject.MESH | Adult | - |
dc.subject.MESH | Asthma | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Genotype | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Receptors, Adrenergic, beta-2 | - |
dc.subject.MESH | Young Adult | - |
dc.title | Effect of beta2-adrenergic receptor polymorphism in asthma control of patients receiving combination treatment. | - |
dc.type | Article | - |
dc.identifier.pmid | 19430548 | - |
dc.identifier.url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2678690/ | - |
dc.contributor.affiliatedAuthor | 김, 승현 | - |
dc.contributor.affiliatedAuthor | 예, 영민 | - |
dc.contributor.affiliatedAuthor | 박, 해심 | - |
dc.type.local | Journal Papers | - |
dc.identifier.doi | 10.3349/ymj.2009.50.2.182 | - |
dc.citation.title | Yonsei medical journal | - |
dc.citation.volume | 50 | - |
dc.citation.number | 2 | - |
dc.citation.date | 2009 | - |
dc.citation.startPage | 182 | - |
dc.citation.endPage | 188 | - |
dc.identifier.bibliographicCitation | Yonsei medical journal, 50(2). : 182-188, 2009 | - |
dc.identifier.eissn | 1976-2437 | - |
dc.relation.journalid | J005135796 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.